177 related articles for article (PubMed ID: 32862200)
1. Squalene synthase promotes the invasion of lung cancer cells via the osteopontin/ERK pathway.
Yang YF; Chang YC; Jan YH; Yang CJ; Huang MS; Hsiao M
Oncogenesis; 2020 Aug; 9(8):78. PubMed ID: 32862200
[TBL] [Abstract][Full Text] [Related]
2. Squalene synthase induces tumor necrosis factor receptor 1 enrichment in lipid rafts to promote lung cancer metastasis.
Yang YF; Jan YH; Liu YP; Yang CJ; Su CY; Chang YC; Lai TC; Chiou J; Tsai HY; Lu J; Shen CN; Shew JY; Lu PJ; Lin YF; Huang MS; Hsiao M
Am J Respir Crit Care Med; 2014 Sep; 190(6):675-87. PubMed ID: 25152164
[TBL] [Abstract][Full Text] [Related]
3. Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation.
Brusselmans K; Timmermans L; Van de Sande T; Van Veldhoven PP; Guan G; Shechter I; Claessens F; Verhoeven G; Swinnen JV
J Biol Chem; 2007 Jun; 282(26):18777-85. PubMed ID: 17483544
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin knockdown inhibits αv,β3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/mTOR pathway.
Zhang H; Guo M; Chen JH; Wang Z; Du XF; Liu PX; Li WH
Cell Physiol Biochem; 2014; 33(4):991-1002. PubMed ID: 24714122
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway.
Fong YC; Liu SC; Huang CY; Li TM; Hsu SF; Kao ST; Tsai FJ; Chen WC; Chen CY; Tang CH
Lung Cancer; 2009 Jun; 64(3):263-70. PubMed ID: 18996613
[TBL] [Abstract][Full Text] [Related]
6. Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer.
Feng YH; Su YC; Lin SF; Lin PR; Wu CL; Tung CL; Li CF; Shieh GS; Shiau AL
BMC Cancer; 2019 Aug; 19(1):791. PubMed ID: 31399076
[TBL] [Abstract][Full Text] [Related]
7. Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice.
Kang CG; Im E; Lee HJ; Lee EO
Bioorg Med Chem Lett; 2017 May; 27(9):1914-1918. PubMed ID: 28359791
[TBL] [Abstract][Full Text] [Related]
8. Rho-associated kinase signaling is required for osteopontin-induced cell invasion through inactivating cofilin in human non-small cell lung cancer cell lines.
Kang CG; Han HJ; Lee HJ; Kim SH; Lee EO
Bioorg Med Chem Lett; 2015 May; 25(9):1956-60. PubMed ID: 25817589
[TBL] [Abstract][Full Text] [Related]
9. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer.
Cheng HC; Liu YP; Shan YS; Huang CY; Lin FC; Lin LC; Lee L; Tsai CH; Hsiao M; Lu PJ
Carcinogenesis; 2013 Nov; 34(11):2452-9. PubMed ID: 23774402
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Das R; Mahabeleshwar GH; Kundu GC
J Biol Chem; 2004 Mar; 279(12):11051-64. PubMed ID: 14704150
[TBL] [Abstract][Full Text] [Related]
11. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.
Wu CY; Wu MS; Chiang EP; Wu CC; Chen YJ; Chen CJ; Chi NH; Chen GH; Lin JT
Gut; 2007 Jun; 56(6):782-9. PubMed ID: 17148500
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis.
Sun BS; You J; Li Y; Zhang ZF; Wang CL
Chin Med J (Engl); 2013; 126(9):1683-8. PubMed ID: 23652051
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of osteopontin promotes cell proliferation and migration in human nasopharyngeal carcinoma and is associated with poor prognosis.
Qin H; Wang R; Wei G; Wang H; Pan G; Hu R; Wei Y; Tang R; Wang J
Eur Arch Otorhinolaryngol; 2018 Feb; 275(2):525-534. PubMed ID: 29214433
[TBL] [Abstract][Full Text] [Related]
14. MAPK pathway and SIRT1 are involved in the down-regulation of secreted osteopontin expression by genistein in metastatic cancer cells.
Khongsti K; Das KB; Das B
Life Sci; 2021 Jan; 265():118787. PubMed ID: 33249095
[TBL] [Abstract][Full Text] [Related]
15. Unveiling the Therapeutic Potential of Squalene Synthase: Deciphering Its Biochemical Mechanism, Disease Implications, and Intriguing Ties to Ferroptosis.
Picón DF; Skouta R
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509391
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of osteopontin in limited-stage small cell lung cancer patients and its mechanism.
Liu F; Bai C; Guo Z
Oncotarget; 2017 Sep; 8(41):70084-70096. PubMed ID: 29050263
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.
Mutrie JC; Chambers AF; Tuck AB
Cancer Biol Ther; 2011 Oct; 12(8):680-90. PubMed ID: 21795853
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy.
Cook AC; Chambers AF; Turley EA; Tuck AB
J Biol Chem; 2006 Aug; 281(34):24381-9. PubMed ID: 16807238
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of osteopontin in metastatic lesions of uterine cervical cancers.
Sakaguchi H; Fujimoto J; Hong BL; Tamaya T
Cancer Lett; 2007 Mar; 247(1):98-102. PubMed ID: 16675104
[TBL] [Abstract][Full Text] [Related]
20. Structure and regulation of mammalian squalene synthase.
Tansey TR; Shechter I
Biochim Biophys Acta; 2000 Dec; 1529(1-3):49-62. PubMed ID: 11111077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
